| abstract |
Disclosed herein is a stable amorphous coprecipitate comprising varenicline tartrate and a pharmaceutically acceptable excipient selected from the group consisting of maltodextrin, lactose monohydrate and 2-hydroxypropyl-β-cyclodextrin, method for the preparation, pharmaceutical compositions, and method of treating thereof. Advantageously, the amorphous coprecipitates of varenicline tartrate disclosed herein have improved physiochemical characteristics that assist in the effective bioavailability. |